LifeMine Therapeutics secures $263 million in dual venture rounds to advance organ transplant aftercare drug

LifeMine Therapeutics announced it has raised a total of $263 million through a $75 million Series D and an $188 million Series F round, opting for private financing rather than an IPO.

The capital will be used to push forward its lead candidate, LIFE‑001, which is being developed to prevent organ failure and offer a safer alternative to lifelong immunosuppressive therapy for transplant recipients.

CEO Greg Verdine said the funding lets the company stay focused on executing its clinical plan and reaching upcoming milestones, while noting that the biotech market’s improving conditions do not dictate the timing of a public offering.

The oversubscribed Series F round reflects investor confidence in the company’s strategy to address a significant unmet need in transplant aftercare.